Table 8 Pharmacokinetic parameters of irinotecan and SN-38

From: A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

   

Irinotecan

SN-38

Arm

Dose (mg m−2)

N

Cl (l h−1)

Cmax (μmol l−1)

AUC (μmol h l−1)

Cmax (μmol l−1)

AUC (μmol h l−1)

AUCc (μmol h l−1)

Metabolic ratio

A

350

30

22.3±7.3

7.91±1.10c

47.8±19.0c

0.151±0.069d

2.08±0.96d

4.16±1.93e

0.044±0.008e

B

125

28

26.8±9.6

2.62±0.39c

14.6±6.9c

0.065±0.021d

0.76±0.29d

3.03±1.17f

0.054±0.014e

C

250

30

24.0±8.4

5.52±0.90c

32.7±13.5c

0.117±0.057d

1.48±0.71d

4.44±2.12e

0.046±0.010e

 

140a

6

30.4±8.2

ND

12.8±3.9

ND

1.4±0.3

4.2±0.9

0.12±0.02b

  1. Data are listed as mean±s.d.
  2. aData obtained in patients receiving 10 mg m−2 irinotecan as 14-day prolonged infusions (N=6).16
  3. bSignificantly different from arms A–C (P<0.001).
  4. cSignificantly different from the other arms of treatment (P<0.001).
  5. dSignificantly different from the other arms of treatment (P<0.05).
  6. eSignificantly different from arm B (P<0.05).
  7. fSignificantly different from arms A and C (P<0.05). Abbreviations: see Materials and methods section. ND=not determined.
Back to article page